eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2016-02-05 4 2 793 796 18558 article SARFARAZ H 1 FARAH K 1 N. GANESH 1 Jawaharlal Cancer Hospital and Research Centre, Idgah Hills, Bhopal - 462 001 (India). Diclofenac (NSAIDs) is an inhibitor of cyclooxygnase. Receiving Diclofenac died prior of completion of the study, exhibiting massive small intestinal ulceration and perforation. The only small intestinal abnormality observed was diffuse hypermia. So we have put our efforts to rule out the toxic menace of diclofenac in rodent’s (Swiss albino) by administrating different does ranging from 0.1mg/kg body weight to 10mg/kg body weight the other doses are 0.3 mg/kg and 1mg/kg. The viable number of crypt cells in jejunal portion of intestine also reduced with increasing doses. Villi and crypt morphology and number were affected according to the dose concentration relatively higher doses induced higher damage and lower doses with lower damage. https://www.biotech-asia.org/vol4no2/histopathologic-study-in-jejunum-portion-of-intestine-by-different-doses-of-diclofenac-sodium-nsaids-in-mice-models/ Non-steroidal anti-inflammatory drug (NSAIDs); Diclofenac sodium; Swiss albino; intestinal cells; Crypt and Villi